CML (Chronic myelogenous leukemia) patients who has consistently treated with Imatinib (Gleevec), have acquired point mutations in tyrosine kinase domain of BCR-ABL fusion gene. Especially, T315I mutation is known as a mutation associated with Imatinibresistance and observed with high frequency.
It is important to monitor patients treated with Imatinibby BCR-ABLfusion gene mutation test to prevent therapy failure due to drug resistance by mutation.
CAT NO.
PNAC-7001
BCR-ABL T315I can be detected by PNAClamp™ BCR-ABL Mutation Detection Kit.
|
Mutations
|
Size
|
|
Exon 6
|
25 tests
|
|
T315I (944C)
|
